264 related articles for article (PubMed ID: 26113605)
1. 15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma.
Mannelli M; Rapizzi E; Fucci R; Canu L; Ercolino T; Luconi M; Young WF
Endocr Relat Cancer; 2015 Aug; 22(4):T83-90. PubMed ID: 26113605
[TBL] [Abstract][Full Text] [Related]
2. MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.
Dona M; Neijman K; Timmers HJLM
Int J Biochem Cell Biol; 2021 May; 134():105949. PubMed ID: 33609747
[TBL] [Abstract][Full Text] [Related]
3. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Vicha A; Taieb D; Pacak K
Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
[TBL] [Abstract][Full Text] [Related]
4. Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma.
Kluckova K; Tennant DA
Cell Tissue Res; 2018 May; 372(2):367-378. PubMed ID: 29450727
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
6. Energy and metabolic alterations in predisposition to pheochromocytomas and paragangliomas: the so-called Warburg (and more) effect, 15 years on.
Neumann HP; de Herder W
Endocr Relat Cancer; 2015 Aug; 22(4):E5-7. PubMed ID: 26273100
[No Abstract] [Full Text] [Related]
7. Molecular pathogenesis of tumorigenesis caused by succinate dehydrogenase defect.
Moosavi B; Zhu XL; Yang WC; Yang GF
Eur J Cell Biol; 2020 Jan; 99(1):151057. PubMed ID: 31810635
[TBL] [Abstract][Full Text] [Related]
8. A conditional mouse mutant in the tumor suppressor SdhD gene unveils a link between p21(WAF1/Cip1) induction and mitochondrial dysfunction.
Millán-Uclés A; Díaz-Castro B; García-Flores P; Báez A; Pérez-Simón JA; López-Barneo J; Piruat JI
PLoS One; 2014; 9(1):e85528. PubMed ID: 24465590
[TBL] [Abstract][Full Text] [Related]
9. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.
Turchini J; Gill AJ
Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631
[No Abstract] [Full Text] [Related]
10. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
[TBL] [Abstract][Full Text] [Related]
11. Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency.
Favier J; Brière JJ; Strompf L; Amar L; Filali M; Jeunemaitre X; Rustin P; Gimenez-Roqueplo AP;
Horm Res; 2005; 63(4):171-9. PubMed ID: 15795514
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
Tevosian SG; Ghayee HK
J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
[TBL] [Abstract][Full Text] [Related]
13. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
14. Genetics of pheochromocytomas and paragangliomas.
Opocher G; Schiavi F
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163
[TBL] [Abstract][Full Text] [Related]
15. Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function.
Rapizzi E; Fucci R; Giannoni E; Canu L; Richter S; Cirri P; Mannelli M
Endocr Relat Cancer; 2015 Jun; 22(3):409-17. PubMed ID: 25808177
[TBL] [Abstract][Full Text] [Related]
16. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.
Gimm O; Armanios M; Dziema H; Neumann HP; Eng C
Cancer Res; 2000 Dec; 60(24):6822-5. PubMed ID: 11156372
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytomas: the (pseudo)-hypoxia hypothesis.
Favier J; Gimenez-Roqueplo AP
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):957-68. PubMed ID: 21115164
[TBL] [Abstract][Full Text] [Related]
18. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
Patel M; Tena I; Jha A; Taieb D; Pacak K
Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
